United States Peptide Cancer Vaccine Market Growth 2025: Key Developments, Emerging Markets | Immatics, Shionogi & Co., Ltd., BrightPath Biotherapeutics, and AMAL Therapeutics (AMAL)

United States Peptide Cancer Vaccine Market size in 2024: USD 0.75 B, projected to USD 4.67 B by 2032, CAGR 26.6%

Japan Cancer Vaccines (all types) Market size in 2024: USD 1.03 B, projected to USD 1.66 B by 2032, CAGR 4%

DataM Intelligence has published a new research report on "Peptide Cancer Vaccine Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

United States: Recent Industry Developments
✅ October 2025: Moderna initiated advanced clinical trials for personalized peptide cancer vaccines targeting solid tumors.
✅ September 2025: Merck expanded research collaborations focused on peptide-based immunotherapies for melanoma.
✅ August 2025: The FDA approved new adjuvant formulations enhancing the efficacy of peptide cancer vaccines in combination therapies.

Japan: Recent Industry Developments
✅ October 2025: Takeda Pharmaceutical advanced development of peptide vaccines targeting gastric and colorectal cancers.
✅ September 2025: Collaborative projects between Japanese biotech firms and research institutes accelerated vaccine candidate evaluations.
✅ August 2025: Increasing government funding supported peptide vaccine research aimed at improving patient-specific immune responses.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/peptide-cancer-vaccine-market?kb

Latest FDA Approvals

Paltonify (paltusotine), an oral somatostatin receptor type 2 agonist with applications for neuroendocrine tumors, received FDA approval in late 2025, signifying progressive regulatory acceptance of peptide-based targeted therapies that modulate hormone receptors, though it is more aligned with peptide therapeutics than vaccines per se.​

There remains no fully FDA-approved synthetic peptide cancer vaccine explicitly listed currently, but multiple peptide vaccines are in advanced trial phases and pathway discussions with the FDA.

Key Players:

Sumitomo dainippon pharma, Sellas, ISA Pharmaceuticals, Immatics, Shionogi & Co., Ltd., BrightPath Biotherapeutics, and AMAL Therapeutics (AMAL).

Recent Clinical Trials

SELLAS Life Sciences' Galinpepimut-S, a peptide vaccine targeting the Wilms Tumor 1 protein prevalent in multiple cancers, is in Phase III trials for acute myeloid leukemia and active in studies related to mesothelioma and solid tumors worldwide, demonstrating promising efficacy and immune activation.​

EO2463, an Off-the-Shelf OncoMimicsTM active immunotherapy peptide vaccine, received FDA fast track designation for follicular lymphoma. The ongoing Phase 1/2 SIDNEY trial evaluates safety and efficacy both as monotherapy and in combination with other agents.

Personalized multi-peptide neoantigen vaccines like PGV001 from Mount Sinai demonstrate safety and promising efficacy in early phase trials for solid tumors including glioblastoma and urothelial cancers, optimized by tumor sequencing for neoantigen identification.​

Elicio Therapeutics' mKRAS-targeting peptide vaccine showed a 77% reduction in risk of death in Phase I trials, highlighting the potential of peptide vaccines to activate durable immune anti-tumor responses.

Growth Forecast Projected:

The Global Peptide Cancer Vaccine Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Peptide Cancer Vaccine Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @: https://www.datamintelligence.com/buy-now-page?report=peptide-cancer-vaccine-market?kb

Key Segments:

By Clinical Trial: ( Phase 1, Phase 2, Phase 3)

By Application: (Prostate Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, Other)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Peptide Cancer Vaccine producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Peptide Cancer Vaccine revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/peptide-cancer-vaccine-market?kb

Latest M&A and Partnerships

Moderna and Merck expanded collaboration on mRNA and peptide cancer vaccine development, leveraging mRNA technology platforms to improve personalized vaccine potentation and delivery.​

BioNTech increased investments in personalized cancer vaccine R&D with €1.33 billion funding in the UK supporting patient recruitment for large-scale clinical trials through 2030, underscoring strategic growth in peptide vaccine and immunotherapy pipelines.​

SELLAS Life Sciences and Memorial Sloan Kettering Cancer Center partnered to develop and commercialize Wilms Tumor 1-targeted vaccines, furthering innovative peptide therapeutic developments.

Get 2-Day Free Trial + 50% OFF DataM Subscription@: https://www.datamintelligence.com/reports-subscription?kb

Recent Procurements and Funding

The US government and private grants are increasingly funding peptide vaccine research, supporting programs like TapImmune's next-gen T-cell response enhancers and Imugene's NCI-supported HER-Vaxx phase II vaccine targeting gastric cancer.​

Organizations focus on scalability and GMP manufacturing agreements with CDMOs specialized in peptide synthesis and vaccine production to meet growing clinical demands.

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.